Form FDA 1572 Statement of Investigator

Form Approved: OMB No. 0910-0014
Expiration Date: February 28, 2019
See OMB Statement on Reverse.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

STATEMENT OF INVESTIGATOR
(TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)

(See instructions on reverse side.)

NOTE: No investigator may participate in an
investigation until he/she provides the sponsor with
a completed, signed Statement of Investigator, Form
FDA 1572 (21 CFR 312.53(c)).

1. NAME AND ADDRESS OF INVESTIGATOR
Name of Clinical Investigator
Address 1
City

Address 2
State/Province/Region

Country

ZIP or Postal Code

2. EDUCATION, TRAINING, AND EXPERIENCE THAT QUALIFY THE INVESTIGATOR AS AN EXPERT IN THE CLINICAL INVESTIGATION OF
THE DRUG FOR THE USE UNDER INVESTIGATION. ONE OF THE FOLLOWING IS PROVIDED (Select one of the following.)
Curriculum Vitae

Other Statement of Qualifications

3. NAME AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL, OR OTHER RESEARCH FACILITY
WHERE THE CLINICAL INVESTIGATION(S) WILL BE CONDUCTED

CONTINUATION PAGE
for Item 3

Name of Medical School, Hospital, or Other Research Facility
Address 1
City

Address 2
State/Province/Region

Country

4. NAME AND ADDRESS OF ANY CLINICAL LABORATORY FACILITIES TO BE USED IN THE STUDY

ZIP or Postal Code

CONTINUATION PAGE
for Item 4

Name of Clinical Laboratory Facility
Address 1
City

Address 2
State/Province/Region

Country

5. NAME AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR
REVIEW AND APPROVAL OF THE STUDY(IES)

ZIP or Postal Code

CONTINUATION PAGE
for Item 5

Name of IRB
Address 1
City

Address 2
State/Province/Region

Country

ZIP or Postal Code

6. NAMES OF SUBINVESTIGATORS (If not applicable, enter “None”)

CONTINUATION PAGE – for Item 6

7. NAME AND CODE NUMBER, IF ANY, OF THE PROTOCOL(S) IN THE IND FOR THE STUDY(IES) TO BE CONDUCTED BY THE INVESTIGATOR

FORM FDA 1572 (2/16)

PREVIOUS EDITION IS OBSOLETE.

Page 1 of 2
PSC Publishing Services (301) 443-6740

EF

8. PROVIDE THE FOLLOWING CLINICAL PROTOCOL INFORMATION. (Select one of the following.)

For Phase 1 investigations, a general outline of the planned investigation including the estimated duration of the study and the
maximum number of subjects that will be involved.
For Phase 2 or 3 investigations, an outline of the study protocol including an approximation of the number of subjects to be
treated with the drug and the number to be employed as controls, if any; the clinical uses to be investigated; characteristics
of subjects by age, sex, and condition; the kind of clinical observations and laboratory tests to be conducted; the estimated
duration of the study; and copies or a description of case report forms to be used.
9. COMMITMENTS

I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make changes in a protocol after
notifying the sponsor, except when necessary to protect the safety, rights, or welfare of subjects.
I agree to personally conduct or supervise the described investigation(s).
I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will
ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review
and approval in 21 CFR Part 56 are met.
I agree to report to the sponsor adverse experiences that occur in the course of the investigation(s) in accordance with 21 CFR
312.64. I have read and understand the information in the investigator’s brochure, including the potential risks and side effects of the
drug.
I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their
obligations in meeting the above commitments.
I agree to maintain adequate and accurate records in accordance with 21 CFR 312.62 and to make those records available for
inspection in accordance with 21 CFR 312.68.
I will ensure that an IRB that complies with the requirements of 21 CFR Part 56 will be responsible for the initial and continuing
review and approval of the clinical investigation. I also agree to promptly report to the IRB all changes in the research activity and all
unanticipated problems involving risks to human subjects or others. Additionally, I will not make any changes in the research without
IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects.
I agree to comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements in
21 CFR Part 312.

INSTRUCTIONS FOR COMPLETING FORM FDA 1572
STATEMENT OF INVESTIGATOR
1. Complete all sections. Provide a separate page if additional space is needed.
2. Provide curriculum vitae or other statement of qualifications as described in Section 2.
3. Provide protocol outline as described in Section 8.
4. Sign and date below.
5. FORWARD THE COMPLETED FORM AND OTHER DOCUMENTS BEING PROVIDED TO THE SPONSOR. The sponsor will
incorporate this information along with other technical data into an Investigational New Drug Application (IND). INVESTIGATORS
SHOULD NOT SEND THIS FORM DIRECTLY TO THE FOOD AND DRUG ADMINISTRATION.
10. DATE (mm/dd/yyyy)

11. SIGNATURE OF INVESTIGATOR

Sign

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)
The information below applies only to requirements of the Paperwork Reduction Act of 1995.
The burden time for this collection of information is estimated to average 100 hours per
response, including the time to review instructions, search existing data sources, gather
and maintain the data needed and complete and review the collection of information. Send
comments regarding this burden estimate or any other aspect of this information collection,
including suggestions for reducing this burden to the address to the right:

Department of Health and Human Services
Food and Drug Administration
Office of Operations
Paperwork Reduction Act (PRA) Staff
[email protected]

“An agency may not conduct or sponsor, and a person is not required to respond to, a
collection of information unless it displays a currently valid OMB number.”

DO NOT SEND YOUR COMPLETED FORM
TO THIS PRA STAFF EMAIL ADDRESS.

FORM FDA 1572 (2/16)

PREVIOUS EDITION IS OBSOLETE.

Page 2 of 2